Hypothesis

Age‑related loss of eosinophils in skeletal muscle diminishes an IL‑5‑driven autocrine circuit that normally limits senescent fibro/adipogenic progenitor (FAP) accumulation; restoring this circuit reduces SASP‑mediated inflammation and improves regeneration.

Mechanistic Rationale

Eosinophils infiltrate injured muscle and secrete IL‑4, which stimulates FAP proliferation while blocking adipogenesis [[https://rupress.org/jem/article/220/7/e20221435/214175/Emerging-functions-of-tissue-resident]]. IL‑5 is required for eosinophil maturation, survival and activation via JAK/STAT, PI3K and MAPK pathways [[https://pmc.ncbi.nlm.nih.gov/articles/PMC11649845/]]. In aged muscle, eosinophil numbers fall [[https://www.drugtargetreview.com/news/64674/rejuvenating-the-elderly-and-frail-using-eosinophils/]], weakening IL‑4‑mediated pro‑regenerative signaling.

We propose that eosinophils also produce IL‑5 in an autocrine fashion, sustaining their own activation and enabling secretion of tissue‑homeostatic factors such as amphiregulin and Wnt ligands [[https://pmc.ncbi.nlm.nih.gov/articles/PMC6013365/]]. These factors promote mesenchymal‑epithelial transitions and enhance clearance of senescent cells through senolytic‑like activity. When eosinophil‑derived IL‑5 wanes with age, eosinophils become less responsive to IL‑33 and microbiota signals, reducing their senolytic capacity. Consequently, senescent FAPs accumulate, secrete SASP cytokines (IL‑6, TNF‑α, TGF‑β) and drive chronic inflammation and fibrosis, impairing muscle repair.

Thus, the eosinophil‑IL‑5 loop acts as a checkpoint that couples eosinophil survival to senescent cell surveillance. Disrupting this loop shifts eosinophils from a reparative to a dysfunctional state, exacerbating age‑related muscle frailty.

Testable Predictions

1. Aged mice show reduced eosinophil IL‑5 production and lower phospho‑STAT5 in muscle eosinophils compared with young mice.
2. Eosinophil‑specific deletion of Il5ra (IL‑5Rα) in young mice recapitulates the aged phenotype: increased senescent FAPs (p16^INK4a^+, SA‑β‑gal^+), elevated SASP, and delayed regeneration after cardiotoxin injury.
3. Adoptive transfer of young wild‑type eosinophils, but not Il5ra‑deficient eosinophils, into aged mice reduces senescent FAP burden, lowers SASP markers, and restores grip strength and endurance.
4. Pharmacologic IL‑5 supplementation in aged mice increases eosinophil activation (phospho‑ERK/AKT), enhances amphiregulin and Wnt ligand secretion, and decreases senescent FAP numbers without altering eosinophil counts.

Experimental Approach

• Flow cytometry and imaging: isolate eosinophils (Siglec‑F^+ CD11b^+ inter^low) from tibialis anterior of young (3 mo) and aged (24 mo) mice; stain for intracellular IL‑5, phospho‑STAT5, and surface activation markers (CD69, CD101).
• Genetic model: generate eosinophil‑specific Il5ra^fl/fl PhiL‑Cre mice; confirm deletion by qPCR. Perform cardiotoxin injury, assess regeneration (central nucleated fibers, cross‑sectional area) at 7 and 14 days, and quantify senescent FAPs (p16^INK4a^+ PDGFRα^+).
• Cell transfer: sort eosinophils from young WT or Il5ra^-^ donors; inject 1×10^5 cells into aged mice 1 day post‑injury; monitor functional outcomes (grip strength, treadmill endurance) and SASP (ELISA for IL‑6, TGF‑β).
• IL‑5 supplementation: treat aged mice with recombinant IL‑5 complex (IL‑5/anti‑IL‑5) or placebo; analyze eosinophil signaling, secretory profile (amphiregulin, Wnt3a) and senescent FAP load.

Falsification: If eosinophil‑specific IL‑5R loss does not increase senescent FAPs or impair regeneration, or if young eosinophil transfer fails to improve outcomes regardless of IL‑5R status, the hypothesis would be refuted.

This framework links eosinophil metabolism to senescent cell control, offering a novel IL‑5‑centric target for mitigating muscle aging.